Viral Vector and Plasmid DNA Manufacturing Market, by Product Type (Viral Vector, Plasma DNA, and Non-viral DNA Vectors), by Therapeutic Application (Cancer, Inherited Disorders, Infectious Diseases, and Others), by End Product (DNA Vaccines, Gene Therapy

Viral Vector and Plasmid DNA Manufacturing Market, by Product Type (Viral Vector, Plasma DNA, and Non-viral DNA Vectors), by Therapeutic Application (Cancer, Inherited Disorders, Infectious Diseases, and Others), by End Product (DNA Vaccines, Gene Therapy, Immunotherapy, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Viral vectors aids in transferring genetic material into target cells and therefore, used in various therapeutic areas. Viral vectors can be significantly used in vaccines development against pathogens such as Mycobacterium tuberculosis, Plasmodium falciparum, HIV, and various bio-threat targets such as filoviruses. Plasmid DNA (pDNA) is gaining traction for clinical research applications in genetic vaccination and gene therapy. It is becoming increasingly useful as novel biotechnology product for DNA vaccines and gene medicines. It can be directly used as a therapeutic agent and indirectly used for various applications such as a starting material for transient transfection to produce transient proteins and viral vector constructs. Furthermore, pDNA is used as a master-template product to support production of new and developing biopharmaceutical products and processes such as cell therapies.
Market Dynamics
Increasing approvals by regulatory authorities for novel gene therapies is expected to drive growth of the gene therapy segment. For instance, in September 2017, GeneOne Life Science, Inc., received approval from the South Korean Ministry of Food and Drug Safety (KMFDS) for an Investigational New Drug application for a Phase I/IIa study of its investigational vaccine, GLS-5300, against the Middle East Respiratory Syndrome coronavirus (MERSCoV). Moreover, in May 2019, AveXis Inc. received the U.S. Food and Drug Administration approval for its Zolgensma (onasemnogene abeparvovec-xioi), an adeno-associated virus vector-based gene therapy for the treatment of pinal muscular atrophy (SMA) in children less than two years old.
Key features of the study:
This report provides in-depth analysis of the global viral vector and plasmid DNA manufacturing market and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022 - 2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global viral vector and plasmid DNA manufacturing market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Lonza Group AG, FinVector Vision Therapies, Cobra Biologics and Pharmaceutical Services, Sigma-Aldrich Co. LLC, VGXI, Inc., VIROVEK, SIRION Biotech GmbH, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Sanofi, Cell and Gene Therapy Catapult, Brammer Bio, and MassBiologics.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The global viral vector and plasmid DNA manufacturing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global viral vector and plasmid DNA manufacturing market
Detailed Segmentation:
Global Viral Vector and Plasmid DNA Manufacturing Market, By Product Type:
Viral Vector
Retroviral Vectors
Adenoviral Vectors
Lentiviral Vectors
Adeno-associated Viral Vectors
Others
Plasma DNA
Non-viral DNA Vectors
Global Viral Vector and Plasmid DNA Manufacturing Market, By Therapeutic Application:
Cancer
Inherited Disorders
Infectious Diseases
Others
Global Viral Vector and Plasmid DNA Manufacturing Market, By End Product:
DNA Vaccines
Gene Therapy
Immunotherapy
Others
Global Viral Vector and Plasmid DNA Manufacturing Market, By Region:
North America
By Product Type:
Viral Vector
Retroviral Vectors
Adenoviral Vectors
Lentiviral Vectors
Adeno-associated Viral Vectors
Others
Plasma DNA
Non-viral DNA Vectors
By Therapeutic Application:
Cancer
Inherited Disorders
Infectious Diseases
Others
By End Product:
DNA Vaccines
Gene Therapy
Immunotherapy
Others
By Country:
U.S.
Canada
Latin America
By Product Type:
Viral Vector
Retroviral Vectors
Adenoviral Vectors
Lentiviral Vectors
Adeno-associated Viral Vectors
Others
Plasma DNA
Non-viral DNA Vectors
By Therapeutic Application:
Cancer
Inherited Disorders
Infectious Diseases
Others
By End Product:
DNA Vaccines
Gene Therapy
Immunotherapy
Others
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Product Type:
Viral Vector
Retroviral Vectors
Adenoviral Vectors
Lentiviral Vectors
Adeno-associated Viral Vectors
Others
Plasma DNA
Non-viral DNA Vectors
By Therapeutic Application:
Cancer
Inherited Disorders
Infectious Diseases
Others
By End Product:
DNA Vaccines
Gene Therapy
Immunotherapy
Others
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Product Type:
Connected
Regular Viral Vector
Retroviral Vectors
Adenoviral Vectors
Lentiviral Vectors
Adeno-associated Viral Vectors
Others
Plasma DNA
Non-viral DNA Vectors
By Therapeutic Application:
Cancer
Inherited Disorders
Infectious Diseases
Others
By End Product:
DNA Vaccines
Gene Therapy
Immunotherapy
Others
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Product Type:
Viral Vector
Retroviral Vectors
Adenoviral Vectors
Lentiviral Vectors
Adeno-associated Viral Vectors
Others
Plasma DNA
Non-viral DNA Vectors
By Therapeutic Application:
Cancer
Inherited Disorders
Infectious Diseases
Others
By End Product:
DNA Vaccines
Gene Therapy
Immunotherapy
Others
By Country:
GCC
Israel
Rest of Middle East
Africa
By Product Type:
Viral Vector
Retroviral Vectors
Adenoviral Vectors
Lentiviral Vectors
Adeno-associated Viral Vectors
Others
Plasma DNA
Non-viral DNA Vectors
By Therapeutic Application:
Cancer
Inherited Disorders
Infectious Diseases
Others
By End Product:
DNA Vaccines
Gene Therapy
Immunotherapy
Others
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Lonza Group AG *
Company Overview
Material Portfolio
Financial Performance
Key Highlights
Market Strategies
FinVector Vision Therapies
Cobra Biologics and Pharmaceutical Services
Sigma-Aldrich Co. LLC
VGXI, Inc.
VIROVEK
SIRION Biotech GmbH
FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
Sanofi
Cell and Gene Therapy Catapult
Brammer Bio
MassBiologics
“*” marked represents similar segmentation in other categories in the respective section.